Heron Therapeutics, Inc. (HRTX)

Market Cap	398.37M
Revenue (ttm)	127.04M
Net Income (ttm)	-110.56M
Shares Out	150.33M
EPS (ttm)	-0.80
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,161,272
Open	2.820
Previous Close	2.800
Day's Range	2.640 - 2.860
52-Week Range	0.500 - 3.220
Beta	1.71
Analysts	Strong Buy
Price Target	5.50 (+107.55%)
Earnings Date	May 9, 2024

About HRTX

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiti...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 26, 1987
• Employees: 126
• Stock Exchange: NASDAQ
• Ticker Symbol: HRTX

Financial Performance

In 2023, HRTX's revenue was $127.04 million, an increase of 17.99% compared to the previous year's $107.67 million. Losses were -$110.56 million, -39.26% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for HRTX stock is "Strong Buy." The 12-month stock price forecast is $5.5, which is an increase of 107.55% from the latest price.

Price Target

$5.5

(107.55% upside)

Analyst Consensus: Strong Buy